Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT

  • Authors:
    • Gabriele Sass
    • Nina Klinger
    • Hüseyin Sirma
    • Said Hashemolhosseini
    • Claus Hellerbrand
    • Daniel Neureiter
    • Henning Wege
    • Matthias Ocker
    • Gisa Tiegs
  • View Affiliations

  • Published online on: May 10, 2011     https://doi.org/10.3892/ijo.2011.1037
  • Pages: 433-442
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The multi-kinase-inhibitor Sorafenib has been shown to prolong survival of patients suffering from hepatocellular carcinoma (HCC). We investigated effects of the serine/threonine kinase inhibitor 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) on experimental HCC growth, and identified mechanisms and target kinases of DMAT. Our results show that DMAT application in vivo reduced tumor growth in a xenotransplant model by interference with tumor cell proliferation. Biochemical parameters and histology following DMAT administration revealed no alterations in liver tissue. Similar to Sorafenib, DMAT interfered with NFκB activation and Wnt-signaling. Of the kinases inhibited by DMAT at almost equimolar IC50, CK2 and PIM-3 were found to be over-expressed or more active in hepatoma cells and human HCC tissue. Knockdown of PIM-3 or CK2 by shRNA revealed that both kinases are important for hepatoma cell proliferation and survival. In conclusion, DMAT reduces HCC growth by interference with NFκB- and Wnt-signaling. PIM-3 and CK2 seem to be important target kinases. Inhibition of these kinases by application of inhibitors, e.g., DMAT, might represent a promising therapeutic approach in future HCC therapy.

Related Articles

Journal Cover

August 2011
Volume 39 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sass G, Klinger N, Sirma H, Hashemolhosseini S, Hellerbrand C, Neureiter D, Wege H, Ocker M and Tiegs G: Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int J Oncol 39: 433-442, 2011.
APA
Sass, G., Klinger, N., Sirma, H., Hashemolhosseini, S., Hellerbrand, C., Neureiter, D. ... Tiegs, G. (2011). Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. International Journal of Oncology, 39, 433-442. https://doi.org/10.3892/ijo.2011.1037
MLA
Sass, G., Klinger, N., Sirma, H., Hashemolhosseini, S., Hellerbrand, C., Neureiter, D., Wege, H., Ocker, M., Tiegs, G."Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT". International Journal of Oncology 39.2 (2011): 433-442.
Chicago
Sass, G., Klinger, N., Sirma, H., Hashemolhosseini, S., Hellerbrand, C., Neureiter, D., Wege, H., Ocker, M., Tiegs, G."Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT". International Journal of Oncology 39, no. 2 (2011): 433-442. https://doi.org/10.3892/ijo.2011.1037